Alnylam Pharmaceuticals
ALNY
#585
Rank
ยฃ31.99 B
Marketcap
ยฃ241.28
Share price
-2.83%
Change (1 day)
24.88%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -ยฃ0.18 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are ยฃ3.21 Billion. In 2024 the company made an earning of -ยฃ0.18 Billion, an increase over its 2023 earnings that were of -ยฃ0.24 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-ยฃ0.18 Billion-24.59%
2023-ยฃ0.24 Billion-67.84%
2022-ยฃ0.73 Billion36.93%
2021-ยฃ0.53 Billion-8.04%
2020-ยฃ0.58 Billion-15.66%
2019-ยฃ0.69 Billion12.23%
2018-ยฃ0.61 Billion62.91%
2017-ยฃ0.38 Billion17.78%
2016-ยฃ0.32 Billion43.44%
2015-ยฃ0.23 Billion60.69%
2014-ยฃ0.14 Billion98.2%
2013-ยฃ69.32 Million
2011-ยฃ40.89 Million27.48%
2010-ยฃ32.08 Million-10.92%
2009-ยฃ36.01 Million95.77%
2008-ยฃ18.4 Million
2006-ยฃ29.47 Million-9.13%
2005-ยฃ32.43 Million34.74%
2004-ยฃ24.07 Million36.79%
2003-ยฃ17.6 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
ยฃ12.19 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ6.78 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ3.90 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-ยฃ0.19 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-ยฃ35.38 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-ยฃ0.12 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ1.60 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.10 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA